Johnson & Johnson accused attorneys for people who have sued the pharmaceutical giant over the company’s talc products of sharing confidential documents with Reuters in what J&J called a “calculated effort” to try its subsidiary’s bankruptcy case in the press.
In a review of recently published scientific studies, investigators at Keck School of Medicine of USC identified a natural barrier to the inner’s sensory cells’ ability to regenerate.
An Illinois jury on July 30 refused to hold Johnson & Johnson liable for a woman’s death from ovarian cancer, which her family blamed on decades of using the company’s talc-based powders.
Positive results from Sellas Life Sciences Group’s Phase I/II trial using galinpepimut-S (GPS) as a combination therapy with pembrolizumab (Keytruda) were announced shortly after similarly positive news was issued from a combination study in which GPS was evaluated as a treatment for mesothelioma.
The U.S. Supreme Court on June 1 declined to hear Johnson & Johnson’s bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products.
Less than a month after submitting an Investigational New Drug (IND) application, Anixa Biosciences ran into a snag with the U.S. Food and Drug Administration as the government agency asked for more information before approving a clinical study on the company’s Chimeric Antigen Receptor-T cell therapy (CAR-T).
As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.
Missouri’s highest court refused to consider Johnson & Johnson’s appeal of a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in its baby powder and other talc products.
The European Medicines Agency (EMA) recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said.
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.